Paper Details

  1. Home
  2. Paper Details

Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy.

Author: D'CruzSanjay, MahajanVidushi, NadaRitambara, SachdevAtul

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This case study details a 7-year-old boy with HBV-related membranous nephropathy (MN) who failed to respond to peginterferon alfa-2b treatment. However, he achieved remission and seroconversion after 3 months of entecavir therapy. This suggests that entecavir is a promising drug for HBV-related glomerulopathy, especially in IFN-resistant cases.
Paper Details　
Original Abstract of the Article :
We report the case of a 7-year-old unimmunized boy who presented with generalized anasarca for the first time, along with nephrotic-range proteinuria, hypoalbuminemia, microscopic hematuria and hypertension. Special investigations revealed ELISA test to be positive for hepatitis B surface antigen (H...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/tropej/fmx058

データ提供：米国国立医学図書館（NLM）

Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy

This case report presents a compelling example of the successful use of [entecavir] in treating [hepatitis B-associated membranous nephropathy (MN)], a rare but serious complication of chronic hepatitis B infection. The authors detail the case of a young boy who presented with [MN] and responded well to treatment with [entecavir] after failing to achieve remission with [peginterferon alfa-2b]. This case study, like a single, resilient tree in a vast desert, offers a glimmer of hope for patients with this challenging condition.

A Promising Treatment Option for HBV-Related Glomerulopathy

The success of [entecavir] in this case provides compelling evidence for its potential as a [valuable treatment option] for [HBV-related glomerulopathy], particularly in patients who do not respond well to [IFN therapy]. This finding highlights the importance of [individualized treatment approaches] and exploring alternative therapies for patients with complex medical conditions.

Exploring the Desert of Treatment Options

This case study underscores the need for [ongoing research and exploration of new therapies] for HBV-related glomerulopathy. It reminds us that the path to effective treatment, like a journey through a vast desert, requires continuous exploration and adaptation.

Dr.Camel's Conclusion

This case report highlights the potential of entecavir as a valuable treatment option for hepatitis B-associated membranous nephropathy. It showcases the importance of personalized treatment approaches and the need for continued research to discover new therapies for this challenging condition. Remember, even in the vast desert of medical complexities, seeking out new pathways and embracing innovation can lead to improved outcomes for patients.
Date :
  1. Date Completed 2019-09-30
  2. Date Revised 2019-09-30
Further Info :

Pubmed ID

28977667

DOI: Digital Object Identifier

10.1093/tropej/fmx058

Related Literature

Article Analysis
・Effects of peginterferon alfa-2b (peg-intron)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.